$BFRI

2 theses

bullish 50%neutral 0%bearish 50%

Avg return (3m)

—

Win rate (3m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 3m ago

$BFRIr/pennystocksTechnical Analysisbearish

u/Traditional_One_3580 · 38d agono track record yet

“author bought BFRI stock (quantity not specified) ahead of FDA approval decision expected on or before 09/28/26”

BFRI FDA Approved - Down 11%

BFRI stock dropped 11% immediately after FDA approval of Ameluz for superficial basal cell carcinoma, despite strong Phase 3 trial data (66% complete clinical response vs 5% placebo, 83% complete clearance of all lesions vs 21%). The author expresses frustration at the counterintuitive market reaction to what appears to be positive regulatory news.

At post $1.36Now $0.81-40.3% since posted3m ago

1d-12.5%

3d-8.8%

1w-14.7%

1m-39.0%

3m—

6m—

1y—

original post →

$BFRIr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 45d ago31 prior · 63% at 3mo

“Watching for completeness, not a core pick”

10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.

Ameluz PDT for superficial basal cell (expanding from actinic keratosis approval) cleared 65.5% vs 4.8% in pivotal trial, with PDUFA Sep 28. High approval probability on paper, but $21M market cap with only ~$5M liquidity and minimal options chain create execution and sizing constraints.

At post $1.56Now $0.81-47.9% since posted3m ago

1d—

3d-6.4%

1w-12.8%

1m-40.1%

3m—

6m—

1y—

original post →

End of results.